Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients

Diabetologia

Volumn 45, Issue 7, 2002, Pages 1011-1016

  Lobmann, R ^a   Ambrosch, A ^b   Schultz, G ^c   Waldmann, K ^a   Schiweck, S ^a   Lehnert, H ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Diabetes mellitus; Matrix metalloproteinases; Wound healing

Indexed keywords

COLLAGEN; GELATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC FOOT; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FOOT ULCER; HOMOGENATE; HUMAN; HUMAN TISSUE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PUNCH BIOPSY; WOUND; WOUND HEALING; ZYMOGRAPHY; BIOPSY; COMPARATIVE STUDY; ENZYMOLOGY; INJURY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SKIN;

BIOPSY; COMPARATIVE STUDY; DIABETES MELLITUS; DIABETIC FOOT; GELATINASE A; HUMAN; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASES; NEUTROPHIL COLLAGENASE; SKIN; TISSUE INHIBITOR-OF METALLOPROTEINASE-2; WOUNDS AND INJURIES; DIABETES COMPLICATIONS; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 8; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0036020282     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0868-8     Document Type: Article

References (51)

1. Long-term prognosis for diabetic patients with foot ulcers
2. Surgical morbidity and the risk of amputation due to infected puncture wounds in diabetics versus nondiabetic adults
3. Increased mortality associated with diabetic foot ulcer
4. Diabetes care research group in Europe
5. Foundation of good ulcer care
6. Incidence of lower limb amputations and diabetes
7. Diabetic foot ulcers: A framework for prevention and care
8. Management of neuropathic ulceration
9. Growth factors and wound healing: Part II. Role in normal and chronic wound healing
10. Molecular and mechanistic validation of delayed healing rat wounds as a model for human chronic wounds
11. Models of wound healing
12. Cutaneous wound healing
13. Chronic wounds: Pathophysiologic and experimental consideration
14. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing
15. Physiology of the chronic wound
16. Age-related differences in the temporal and spatial regulation of matrix metalloproteinases (MMPs) in normal skin and acute wounds of healthy humans
17. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds
18. Role of cytokines in healing chronic skin wounds
19. Gelatinase activities in wounds of healing-impaired mice versus wounds of non-healing-impaired mice
20. Molecular analysis of different phases in human wound healing
21. Biochemical analysis of acute and chronic wound environments
22. Matrix metalloproteinases in skin
23. Differential expression of matrix metalloproteinases and their physiological inhibitors in acute murine skin wounds
24. Matrix metalloproteinases in wound repair
25. Matrix metalloproteinases
26. Dynamics of the matrix metalloproteinases MMP-1 and MMP-8 in acute open human dermal wounds
27. Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing
28. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair
29. Metalloproteinase activation cascade after burn injury: A longitudinal analysis of the human wound environment
30. Tissue inhibitors of metalloproteinases: Evolution, structure and function
31. Metalloproteinase inhibitors and wound healing: A novel enhance of wound strength
32. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing
33. Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds
34. Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors
35. The proteolytic environment of chronic wounds
36. Growth factors and wound healing: Biochemical properties of growth factors and their receptors
37. Cytokine regulation of metalloproteinase gene expression
38. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids
39. Proteinases, their inhibitors, and cytokine profiles in acute wound fluid
40. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers
41. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9
42. Expression of MMP-8 and TIMP-2 in diabetic and non-diabetic wounds
43. MMP-8 is the predominant collagenase in healing wounds and non-healing ulcers
44. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds
45. Wound healing. New modalities for a new millennium
46. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula
47. Becaplermin gel (PDGF-BB) as topical wound therapy
48. Effects of growth factors and insulin on the in-vitro-proliferation of fibroblasts from patients with type-2 diabetes and normal controls
49. The future of recombinant growth factors in wound healing
50. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers
51. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: Relationship to structure of the enzyme